Nanomedicines for Breast Cancer Theranostics addresses the translational aspects and clinical perspectives of breast cancer nanomedicine from a multidisciplinary perspective. The book summarizes research efforts at the preclinical and clinical stage of nanostructures and nanomedicine for dealing with the important challenge of nanomedicine translation in breast cancer theranostics. This book is an important resource for those working in both academia and industry, focusing on hot topics in biomaterials, biomedical engineering, drug delivery and oncology.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Contributors - p. xiii 6. Biography - p. xvii 7. Preface - p. xxi 8. Acknowledgment - p. xxiii 9. Part 1. Nanomedicine - p. xxiii 10. 1. Nanomedicine: next generation modality of breast cancer therapeutics - p. 3 11. 2. Physical and chemical properties of nanomaterials - p. 17 12. 3. Biological prospectives of hybrid nanostructures - p. 33 13. 4. Novel hybrid nanostructure for breast cancer application - p. 57 14. Part 2. Theranostics - p. 67 15. 5. Synergy between nanoparticles and breast cancer theranostics - p. 71 16. 6. Remotely stimulated nanomedicine for breast cancer therapy - p. 107 17. 7. Functional nanostructures for drug resistance breast cancer theranostics - p. 131 18. 8. Nanomedicine for early diagnosis of breast cancer - p. 153 19. 9. Nanomedicine strategies for chemoresistance breast cancer theranostics - p. 175 20. Part 3. Clinical translation - p. 189 21. 10. Cellular interaction and toxicity of nanostructures - p. 193 22. 11. Nanopharmacokinetics, pharmacodynamics (PK/PD), and clinical relationship - p. 245 23. 12. A new approach for cancer treatment: from specific induction of breast cancer to innovative gold-nanoparticle mediated thermal therapies - p. 269 24. 13. Development in efficacy assessment in relevant oncology models for breast cancer nanomedicine - p. 299 25. 14. Consensus protocols for animal experimentation and nanomedicine trials at clinical stage in breast cancer - p. 331 26. 15. Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines - p. 351 27. 16. Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine - p. 371 28. Index - p. 405
Nanomedicines for Breast Cancer Theranostics addresses the translational aspects and clinical perspectives of breast cancer nanomedicine from a multidisciplinary perspective. The book summarizes research efforts at the preclinical and clinical stage of nanostructures and nanomedicine for dealing with the important challenge of nanomedicine translation in breast cancer theranostics. This book is an important resource for those working in both academia and industry, focusing on hot topics in biomaterials, biomedical engineering, drug delivery and oncology.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Contributors - p. xiii 6. Biography - p. xvii 7. Preface - p. xxi 8. Acknowledgment - p. xxiii 9. Part 1. Nanomedicine - p. xxiii 10. 1. Nanomedicine: next generation modality of breast cancer therapeutics - p. 3 11. 2. Physical and chemical properties of nanomaterials - p. 17 12. 3. Biological prospectives of hybrid nanostructures - p. 33 13. 4. Novel hybrid nanostructure for breast cancer application - p. 57 14. Part 2. Theranostics - p. 67 15. 5. Synergy between nanoparticles and breast cancer theranostics - p. 71 16. 6. Remotely stimulated nanomedicine for breast cancer therapy - p. 107 17. 7. Functional nanostructures for drug resistance breast cancer theranostics - p. 131 18. 8. Nanomedicine for early diagnosis of breast cancer - p. 153 19. 9. Nanomedicine strategies for chemoresistance breast cancer theranostics - p. 175 20. Part 3. Clinical translation - p. 189 21. 10. Cellular interaction and toxicity of nanostructures - p. 193 22. 11. Nanopharmacokinetics, pharmacodynamics (PK/PD), and clinical relationship - p. 245 23. 12. A new approach for cancer treatment: from specific induction of breast cancer to innovative gold-nanoparticle mediated thermal therapies - p. 269 24. 13. Development in efficacy assessment in relevant oncology models for breast cancer nanomedicine - p. 299 25. 14. Consensus protocols for animal experimentation and nanomedicine trials at clinical stage in breast cancer - p. 331 26. 15. Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines - p. 351 27. 16. Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine - p. 371 28. Index - p. 405
